Apyx Medical Inc (APYX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Apyx Medical Inc stock (APYX) is currently trading at $3.94. Apyx Medical Inc PS ratio (Price-to-Sales) is 2.75. Analyst consensus price target for APYX is $6.40. WallStSmart rates APYX as Sell.
- APYX PE ratio analysis and historical PE chart
- APYX PS ratio (Price-to-Sales) history and trend
- APYX intrinsic value — DCF, Graham Number, EPV models
- APYX stock price prediction 2025 2026 2027 2028 2029 2030
- APYX fair value vs current price
- APYX insider transactions and insider buying
- Is APYX undervalued or overvalued?
- Apyx Medical Inc financial analysis — revenue, earnings, cash flow
- APYX Piotroski F-Score and Altman Z-Score
- APYX analyst price target and Smart Rating
Apyx Medical Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Apyx Medical Inc (APYX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, revenue growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Apyx Medical Inc (APYX) Key Strengths (2)
Growing significantly faster than its price suggests
Revenue surging 34.70% year-over-year
Supporting Valuation Data
Apyx Medical Inc (APYX) Areas to Watch (7)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive at 9.9x book value
Micro-cap company with very limited liquidity and high volatility
Revenue is fairly priced at 2.75x sales
Moderate institutional interest at 46.15%
Supporting Valuation Data
Apyx Medical Inc (APYX) Detailed Analysis Report
Overall Assessment
This company scores 38/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Revenue Growth. Valuation metrics including PEG Ratio (0.59) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 34.70%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Operating Margin. Some valuation metrics including Price/Sales (2.75), Price/Book (9.90) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -76.10%, Operating Margin at 0.06%, Profit Margin at -21.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -76.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 34.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
APYX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
APYX's Price-to-Sales ratio of 2.75x trades at a deep discount to its historical average of 7.07x (33th percentile). The current valuation is 87% below its historical high of 21.52x set in Jan 2019, and 263% above its historical low of 0.76x in Apr 2025. Over the past 12 months, the PS ratio has expanded from ~1.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Apyx Medical Inc (APYX) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Apyx Medical Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 53M with 35% growth year-over-year. The company is currently unprofitable, posting a -21.2% profit margin.
Key Findings
Revenue growing at 35% YoY, reaching 53M. This pace significantly outperforms most MEDICAL DEVICES peers.
The company is unprofitable with a -21.2% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Apyx Medical Inc maintain 35%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.66, so expect amplified moves relative to the broader market.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Apyx Medical Inc.
Bottom Line
Apyx Medical Inc is a high-conviction growth story with revenue accelerating at 35% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -21.2% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(4 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:25:23 AM
About Apyx Medical Inc(APYX)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.